Healthy Volunteers Clinical Trial
— COMPETEOfficial title:
Effets de la tDCS Sur la Performance Sportive de 2 Profils d'athlètes : Explosifs (Sauteurs de Haut Niveau et Amateur) et Endurants (Cyclistes de Haut Niveau et Amateur)
The study aims to compare the effects of tDCS applied on the dorsolateral prefrontal cortex (dlPFC) vs sham on the neuromuscular system. Two types of athletes will benefit from stimulation: jumper and cyclists. Short and long term effects are assesed by electromyographic records, experimental tasks and self-rated scales.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | April 2020 |
Est. primary completion date | April 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Man older than 18 years old - Right-handed - Signed informed Consent form - Subject affiliated to or beneficing from a French social security regime - According to groups : - Part A : - Group S1 : High level jump practice : more 4000 hours of practice during the last five years - Group S2 : Amateur jump practice : less 4000 hours of practice during the last five years - Part B : - Group C1 : High level cycling practice: more 4000 hours of practice during the last five years - Group C2 : Amateur cycling practice: less 4000 hours of practice during the last five years - Group T : Sedentary : less two hours of recreationally practice of sport by week Exclusion Criteria: - Younger than18 years old - Left-handed - Subject under measure of protection or guardianship of justice - Subject beneficiary from a legal protection regime - Subject unlikely to cooperate or low cooperation stated by investigator - Subject not covered by social security - Suject with comorbidities : addictive (except : tea, coffee, tobacco), psychiatric, severe somatic pathologies (specially tumors, degenerative disease) or progressive neurologic pathologie - Subject being in the exclusion period of another study or provided for by the "National Volunteer File" |
Country | Name | City | State |
---|---|---|---|
France | CHU Besancon - Clinical Psychiatric Department | Besancon | |
France | EA4660- C3S, Culture, Sport, Santé, Société | Besançon |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Besancon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance (in meters) measured during jumps | Performance measurement (in meters) during the three types of jumps (long jump, squat jump and countermovement jump) before and after tDCS session | Day 5 | |
Secondary | Average power during the time trial before and after 10 tDCS sessions | Average power (in watts) measured during a 20min time trial before and after 10 tDCS sessions for 5 days | Day 35 | |
Secondary | BIS-10 scores | Compared scores from the French version of the Barratt Impulsiveness Scale (BIS-10). The French version of the BIS-10 is a self-rated 34 item questionnaire, composed by three subscales: motor-impulsivity, cognitive-impulsivity and non-planning-impulsivity. Each item is scored on a 0 to 4 points scale. Higher scores indicate higher levels of impulsivity. | Day 60 | |
Secondary | MCQ scores | Compared scores from the French version of the Monetary Choice Questionnaire. The MCQ is a self-rated 27 item questionnaire which assessed the discounting. Delay discounting is the decline in the present value of a reward with delay to its receipt. Example item: " Would you prefer 25€ today or 75€ in 15 days? " For each item, subjects must choose between a low immediate reward and a higher delayed reward. Waiting times vary from 7 days to 186 days, and rewards are divides into 3 magnitudes: low (25-35€), medium (50-60€), high (75-85€). This will allow assessing: the influence of the the magnitude of the difference between the two rewards proposed, the impact of the time on the reward's subjective value (speed at which the reward is devalued over time), reflected in the k index. This index is calculated separately for each magnitude, and an average index is calculated for each subject. The more the k index is high, the more the subject is considered impulsive. |
Day 60 | |
Secondary | Stroop task | Compared results from the experimental Stroop task, assessing response inhibition. | Day 60 | |
Secondary | Go/No-Go task | Compared results from the experimental Go/No-Go task, assessing response inhibition. | Day 60 | |
Secondary | Effort Expenditure for Reward Task | Compared results from the experimental Effort Expenditure for Reward Task, assessing motivation | Day 60 | |
Secondary | Balloon Analog Risk Task | Compared results from the experimental Balloon Analog Risk task, assessing impulsivity | Day 60 | |
Secondary | QIDS-C16 scale | Compared scores from the French version of the Quick Inventory of Depressive Symptomatology. The QIDS-C16 is a 16 item questionnaire completed by the clinician to assess the depressive symptomatology and the severity of the depression. These 16 items are constructed around the 9 following symptoms: sad mood, concentration, autocriticism, suicidal thoughts, ahnedonia, fatigue, sleep disorders, appetite/weight changes, psychomotor retardation/agitation. This scaled is based on the intensity of each symptom in the 7 last days, regardless of its chronicity or its recent apparition. Each symptom is rated 0 to 3. The total score thus vary from 0 to 27. |
Day 60 | |
Secondary | QIDS-SR16 scale | Compared scores from the French version of the Quick Inventory of Depressive Symptomatology. The QIDS-SR16 is a self-rated 16 item questionnaire, assessing the intensity of depressive symptomatology. These 16 items are constructed around the 9 following symptoms: sad mood, concentration, autocriticism, suicidal thoughts, ahnedonia, fatigue, sleep disorders, appetite/weight changes, psychomotor retardation/agitation. This scaled is based on the intensity of each symptom in the 7 last days, regardless of its chronicity or its recent apparition. Each symptom is rated 0 to 3. The total score thus vary from 0 to 27. |
Day 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |